This segment focuses on the development, manufacturing, and commercialization of the INTERCEPT Blood System designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion. The technology utilizes a proprietary method to control biological replication, reducing the risk of transfusion-transmitted infections. Research and development efforts are directed towards expanding the system's capabilities to address emerging pathogens and improve ease of use. The system is sold through a direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Future opportunities include expanding market penetration and developing new applications for pathogen reduction in plasma-derived products.

This segment is dedicated to the development and commercialization of the INTERCEPT Blood System for red blood cells, which aims to inactivate blood-borne pathogens in red blood cells donated for transfusion. The technology is designed to improve the safety of red blood cell transfusions, particularly in regions with a high prevalence of transfusion-transmissible infections. Research and development activities focus on optimizing the treatment process, expanding the system's effectiveness against a broader range of pathogens, and conducting clinical trials to demonstrate its clinical benefits. The segment's market positioning is focused on providing a comprehensive solution for blood safety, addressing the unmet need for pathogen reduction in red blood cell transfusions. Future growth potential lies in securing regulatory approvals in key markets and expanding the system's adoption in routine clinical practice.

This segment focuses on utilizing the INTERCEPT Blood System's plasma system to produce pathogen-reduced cryoprecipitated fibrinogen complex. This complex is used for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen-reduced plasma, cryoprecipitate reduced. Research and development efforts are geared towards optimizing the production process, enhancing the quality and efficacy of the fibrinogen complex, and expanding its applications in various clinical settings. The segment addresses a critical need in managing bleeding disorders and improving patient outcomes in trauma and surgical settings. Future opportunities include expanding market access, conducting clinical trials to demonstrate the clinical benefits of the pathogen-reduced fibrinogen complex, and developing new formulations and delivery methods.